Ocugen Provides Business Update with First Quarter 2026 Financial Results
Ocugen reported positive Phase 2 data for OCU410, showing a statistically significant 31% reduction in lesion growth, and completed enrollment for registration trials of OCU400 and OCU410ST. The company closed a private offering of $115 million in convertible notes, extending its cash runway into 2028, with $32.7 million used to retire higher-interest Avenue debt.
Key figures
- Revenue
- 1533000
- Revenue Yoy
- 3.5%
- Deal Value Usd
- 115000000
- Cash runway
- into 2028
- Ga expenses
- 8117000
- Rd expenses
- 11255000
- Cash pro forma
- 112100000
- Operating expenses
- 19372000
- Ocu410 lesion reduction
- 31%
- Ocu400 phase3 enrollment
- 140
- Ocu410st phase23 enrollment
- 63
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.